Roche announces phase III study of Avastin

Since the US Food and Drug Administration (FDA) announced recently its revocation of Avastin® (bevacizumab) as a treatment for metastatic breast cancer, Roche has confirmed that it will continue its research with the drug. Phase III studies will test the drug in combination with paclitaxel for MBC patients as a first line of treatment. In addition, Roche will also conduct studies to determine the biomarker/s for the subgroup of patients who are exceptionally receptive to treatment with Avastin.

5 6 7 8
© 2004–2011 Donna Peach. All rights reserved.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s